Endocrine Abstracts (2010) 22 P549

IGF(CA)19 and IGFBP-3-202A/C gene polymorphism in patients with acromegaly

Fulya Akin1, Sebahat Turgut2, Bayram Cirak3 & Raziye Kursunluoglu2

1Department of Endocrinology, Pamukkale University, Denizli, Turkey; 2Department of Physiology, Pamukkale University, Denizli, Turkey; 3Department of Neurosurgery, Pamukkale University, Denizli, Turkey.

Aims: We aimed to investigate IGF1 and IGFBP3 gene polymorphisms in patients with acromegaly.

Methods: We included 34 patients with acromegaly and 37 healthy subjects to study. At baseline examinations, antropometric measurements were done. Genomic DNA from the patients and controls were prepared. Serum, glucose, insulin, total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, GH, IGF1 and IGFBP3 levels of subjects were analyzed.

Results: The frequency of genotype IGF1(CA)19 and IGFBP3-202 A/C gene was significantly different between control and patients. In acromegalic patients, a significant difference in the serum IGF1 levels and LDL cholesterol levels among the three IGF(CA)19 genotype. LDL levels were positively correlated with IGF1. Subjects having >194 bp genotype had higher IGF1 and LDL cholesterol levels.We observed that the patients with 194 bp genotype have more invasive and bigger tumors and they require adjunctive therapies. Clinical characteristics among the three IGFBP3-202 A/C genotype, AA, AC and CC, did not display any significant difference.

Conclusion: In our study, 194 bp allele (20 CA repeats) of the IGF1 promoter have higher circulating IGF1 levels than others. We have found that the patients with 194 bp genotype are the resistant patients with active disease and they required high dose medication. We think this study will help to define the patients, who are resistant to drug therapy, and possible cardiovascular disease.

Article tools

My recent searches

No recent searches.